Stellar Capital Management Portfolio holdings
Top Buys
| 1 |
Gilead Sciences
GILD
|
+$1.25M |
| 2 |
Chevron
CVX
|
+$898K |
| 3 |
iShares MSCI EAFE ETF
EFA
|
+$648K |
| 4 |
PepsiCo
PEP
|
+$520K |
| 5 |
ExxonMobil
XOM
|
+$492K |
Top Sells
| 1 |
Edwards Lifesciences
EW
|
+$793K |
| 2 |
UGI
UGI
|
+$203K |
| 3 |
IBM
IBM
|
+$35.8K |
| 4 |
ResMed
RMD
|
+$32.5K |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$10.6K |
Sector Composition
| 1 | Technology | 15.83% |
| 2 | Healthcare | 13.98% |
| 3 | Industrials | 12.78% |
| 4 | Energy | 8.46% |
| 5 | Financials | 8.39% |
Similar funds
Stellar Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, Stellar Capital Management held 68 positions worth $103M, up 11% from $92.8M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Stellar Capital Management deployed $11.7M of net new capital in Q1 2015, opening 4 new positions and adding to 52 existing holdings. Its largest new stake was Gilead Sciences: 12,322 shares worth $1.21M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 18% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Edwards Lifesciences, an estimated $793K trimmed.
- Stellar Capital Management's largest Q1 2015 buy was Gilead Sciences: 12,322 shares worth $1.21M.
- Stellar Capital Management added most to Chevron in Q1 2015, an estimated $898K increase.
- Stellar Capital Management's biggest Q1 2015 reduction was Edwards Lifesciences, cutting an estimated $793K.
- Stellar Capital Management fully exited UGI in Q1 2015, selling an estimated $203K.
- Stellar Capital Management's ten largest holdings make up 32% of its $103M portfolio in Q1 2015.
- Stellar Capital Management opened 4 new positions and closed 1 in Q1 2015.
- Stellar Capital Management's portfolio value rose 11% quarter-over-quarter to $103M.
Based on Stellar Capital Management's 13F filing for Q1 2015, filed 27 Apr 2015.